ImmuneOnco Biopharmaceuticals (Shanghai) Full Year 2024 Earnings: CN¥0.84 loss per share (vs CN¥1.05 loss in FY 2023)

Simply Wall St·05/01/2025 06:21:45

Listen to the news

ImmuneOnco Biopharmaceuticals (Shanghai) (HKG:1541) Full Year 2024 Results

Key Financial Results

Revenue: CN¥79.5m (up by CN¥71.8m from FY 2023).
Net loss: CN¥315.9m (loss narrowed by 17% from FY 2023).
CN¥0.84 loss per share (improved from CN¥1.05 loss in FY 2023).

This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality.

1541 Products In Clinical Trials

Phase I: 12.
Phase III: 2.

revenue-and-expenses-breakdown — SEHK:1541 Revenue and Expenses Breakdown May 1st 2025

All figures shown in the chart above are for the trailing 12 month (TTM) period

The primary driver behind last 12 months revenue was the United States of America segment contributing a total revenue of CN¥74.0m (93% of total revenue). The largest operating expense was Research & Development (R&D) costs, amounting to CN¥322.8m (82% of total expenses). Explore how 1541's revenue and expenses shape its earnings.

ImmuneOnco Biopharmaceuticals (Shanghai) shares are down 2.3% from a week ago.

Risk Analysis

It is worth noting though that we have found 1 warning sign for ImmuneOnco Biopharmaceuticals (Shanghai) that you need to take into consideration.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

FAQ

Fee Schedule Open Account Deposit & Withdrawal Trading

Terms & Conditions

Client Agreement Privacy Policy Data Disclaimer Security Tips

About Webull

About us Webull Promotions Contact information Announcements

Service Email : service@webull.hkBusiness Cooperation : marketinghk@webull.hk

Risk Disclosure: The content of this page is not an investment advice and does not constitute any offer or solicitation to offer or recommendation of any investment product. It is for general purposes only and does not take into account your individual needs, investment objectives and specific financial circumstances. All investments involve risk and the past performance of securities, or financial products does not guarantee future results or returns. Keep in mind that while diversification may help spread risk it does not assure a profit, or protect against loss, in a down market. There is always the potential of losing money when you invest in securities, or other financial products. Investors should consider their investment objectives and risks carefully before investing. For more details, please refer to risk disclosure.
① During the campaign period, US stocks, US stocks short selling, US stock options, Hong Kong stocks, and A-shares trading will maintain at $0 commission, and no subscription/redemption fees for mutual fund transactions. $0 fee offer has a time limit, until further notice. For more information, please visit: https://www.webull.hk/pricing
Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.

Language

English